Document:

mdrx-ex101_304.htm

U.S. Department of Justice

Civil Division

AJM:ECC:KCHauser

46-78-125617-748-3308

_____________________________________________________________________

Washington, DC 20530

 

 

April 8, 2020

By Email

 

Joshua Levy

Aaron Katz

Ropes & Gray, LLP

800 Boylston St

Boston, MA 02199

joshua.levy@ropesgray.com

 

Re:Practice Fusion Settlement 

 

Dear Counsel:

 

Practice Fusion, Inc., and its parent corporation Allscripts Healthcare, LLC (collectively “the Company”) has requested that the United States, through the United States Attorney’s Office for the District of Vermont and the Civil Division of the United States Department of Justice (collectively, “the Government”), agree to amend the Payment Schedule contained in Exhibit A to the Settlement Agreement between the Parties executed on January 26, 2020.  The Company states that due to certain financial difficulties, it is necessary to adjust the schedule for remaining payments.

 

Accordingly, the Government agrees to amend Exhibit A as follows: Remaining payments under this Settlement Agreement will be made on the dates and in the amounts reflected in the revised payment schedule attached as Exhibit 1 to this letter agreement. All other payment terms, payment amounts, and schedules of the Settlement Agreement remain unchanged and in effect.  All Settlement Documents shall remain in full force and effect. This agreement to amend this term of the Settlement Agreement does not purport to change any other provision, or term.

 

2

 

 

If the Company agrees with this amendment, please countersign a copy of this letter and return it to me at your earliest convenience. 

 

 Regards,

 

/s/ Kelley C. Hauser

Kelley C. Hauser

Christelle Klovers

Trial Attorneys

U.S. DEPARTMENT OF JUSTICE

CIVIL DIVISION 

 

 

 

 

 

 

cc:Owen Foster

Assistant United States Attorney

District of Vermont

 

Attachment

 

 

3

 

On behalf of the United States:

 

 

 

DATED:   4/21/2020BY:

  /s/ Owen Foster

OWEN FOSTER

Assistant United States Attorney

United States Attorney’s Office

District of Vermont

 

 

 

 

DATED:   4/21/2020BY:  /s/ Kelly Hauser

KELLEY HAUSER 

EDWARD CROOKE

Commercial Litigation Branch

Civil Division

United States Department of Justice

 

 

On behalf of Practice Fusion:

 

 

 

DATED:  __4/08/2020BY:/s/ Eric L. Jacobson

ERIC L. JACOBSON, ESQ. 

Secretary

Practice Fusion, Inc.

 

 

DATED: 4/20/2020BY:  /s/ Joshua Levy

JOSHUA LEVY

AARON KATZ

PATRICK WELSH

Counsel for Practice Fusion, Inc.

 

4

 

EXHIBIT A

 

Federal Settlement Amount Payment Schedule

 

		
	
Due Date
	
Payment

	
Within 10 calendar days of the Effective Date of this Agreement
	
$28,343,738 plus accrued interest

	
No later than three months after the Effective Date of this Agreement
	
$14,171,869 plus accrued interest

	
No later than six months after the Effective Date of this Agreement
	
$14,171,869 plus accrued interest

	
No later than nine months after the Effective Date of this Agreement
	
$28,343,738 plus accrued interest

	
No later than twelve months after the Effective Date of this Agreement
	
$28,343,738 plus accrued interestExhibit

Exhibit 10.2

FOURTH ADDENDUM

THIS ADDENDUM, made and entered into this 7th day of April, 2020, to that Lease dated December 16, 2010, by and between CRESTVIEW, LLC, a Colorado limited liability company (herein called “Landlord”) and MIRAGEN THERAPEUTICS, INC., a Delaware corporation (herein called “Tenant”).

The parties hereto agree to modify said Lease, effective as of the date of last signature below, as follows:

		
	1.
	Paragraph 1n is modified to read as follows:

n.    “Primary Lease Term.” The term of the Lease shall commence at 12:01 a.m. on the 1st day of January, 2011 and shall terminate at 12:00 midnight on the 31st day of December, 2021, a term of eleven (11) years.

2.    Paragraph 4 is modified to read as follows:

RENT.  Tenant agrees to pay to Landlord as Base Rent, without prior notice or demand, the following amounts:
Schedule of Base Rent
         Month(s)                          Monthly Base Rent                    Annual Base Rent    
January 2011-May 2011           $15,627.50                    $78,137.50 (Only 5 Months)    
 
June 2011-May 2012            $15,627.50                  $187,530.00             
    
June 2012-May 2013            $16,174.46                  $194,093.52
    
June 2013-May 2014            $16,740.57                  $200,886.84

June 2014-May 2015            $17,326.49                  $207,917.88

June 2015-September 2015        $16,185.63                  $64,742.52 (Only 4 Months)

October 2015                $18,262.20                  $18,262.20 (Only 1 Month)

November 2015            $26,914.54                  $26,914.54 (Only 1 Month)

December 2015-November 2016    $26,914.54                  $322,974.48

December 2016-November 2017    $31,481.79                  $377,781.48

December 2017-November 2018    $32,504.95                  $390,059.40

December 2018-November 2019    $33,561.36                  $402,736.32

December 2019-December 2020    $34,652.10                  $450,477.30 (13 Months)

January 2021-December 2021    $35,778.29                  $429,339.48

Total Base Rent:                               $3,351,853.46

Tenant shall begin to pay the Base Rent on the date the Primary Lease Term commences and thereafter on the first day of each month during the term hereof. Except as provided herein, all Rents shall be paid in advance, without notice, set off, abatement, counterclaim, deduction or diminution, at The Colorado Group, Inc., 3434 47th Street, Suite 220, Boulder, Colorado 80301, Attn: Susan Chrisman, or at such place as Landlord, from time-to-time, designates in writing. In addition, Tenant shall pay to Landlord Tenant’s Pro Rata Share of Operating Expenses as provided herein and such other charges as are required by the terms of this Lease to be paid by Tenant which shall be referred to herein as “Additional Rent.” Landlord shall have the same rights as to the Additional Rent as it has in the payment of Base Rent.  At no time shall Tenant’s Rent obligation be less than the Base Rent amount set forth above.

3.    Other than as modified herein, all terms and conditions of the Lease shall remain unchanged.

IN WITNESS WHEREOF, the undersigned have executed this document as of the date above written.

	
					
	LANDLORD:
	 
	TENANT:

	CRESTVIEW, LLC
	 
	MIRAGEN THERAPEUTICS, INC.

	 
	 
	 
	 
	 

	By:
	/s/ Steven P. Chrisman
	 
	By:
	/s/ Jason A. Leverone

	 
	 
	 
	 
	 

	 
	Steven P. Chrisman
	 
	 
	Jason A. Leverone

	 
	Manager
	 
	 
	Chief Financial Officer

	 
	864 W. South Boulder Road, Suite 200
	 
	 
	6200 Lookout Road, Suite 100

	 
	Louisville, Colorado 80027
	 
	 
	Boulder, Colorado 80301

	 
	Tax I.D. 84-1445718
	 
	 
	Tax I.D. 20-4362468Exhibit

Exhibit 10.3
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN REDACTED BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK, “[*]”.

	
																																																														
	FDP Research Subaward Agreement
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	Amendment (Number
	9
	)
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Pass-Through Entity (PTE)
	Subrecipient
	 

	 
	 
	 
	 
	 
	 

	Yale University
	 
	 
	Entity Name
	Miragen Therapeutics, Inc.
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	gcat5@yale.edu
	 
	Email Address
	jleverone@miragenrx.com
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	[*], MD
	 
	Principal Investigator
	Rusty Montgomery, MD
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Project Title:
	Mir-29 mimicry as a therapy for pulmonary fibrosis
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	PTE Federal Award No:
	 
	 
	 
	Federal Awarding Agency:
	 
	 

	 
	5UH3HL123886-05 REVISED
	 
	 
	 
	 
	National Institutes of Health (NIH)
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Subaward Revised  Period  of  Performance:
	Amount Funded This Action:
	 
	 
	Subaward No:
	 

	Start Date:
	September 1, 2018
	End Date:
	Jun 30, 2020
	 
	 
	$ [*]
	 
	 
	 
	GR1004495  (CON-80001453)
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Total Amount of Federal Funds Obligated to Date:
	 
	 
	 
	Cost Share
	Subject to FFATA:
	Automatic Carryover:
	 

	 
	 
	 
	$ [*]
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	☐
	Yes
	☒
	No
	 
	☒
	Yes
	☐
	No
	 
	☐
	Yes
	☒
	No
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Amendment(s) to Original Terms and Conditions
This Amendment revises the above-referenced Research Subaward Agreement as follows:
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	•    A detailed budget follows and is hereby incorporated into this amendment as Appendix A.Additional funds in the amount of [*] are hereby authorized as follows:

Direct Costs:  [*]
Indirect Costs: [*]
Total Costs: [*]

	 
	 

	 
	•    If carryover is not automatic (No selected above), the "Total Amount of Federal Funds Obligated to Date" stated above may not reflect the actual balance available. The Subrecipient is responsible for tracking unobligated balances and subsequent carryover approvals from prior budget periods. In the event that funding was not fully expended by the Subrecipient during the prior period, the Subrecipient is not authorized to use funds from any prior periods, unless approval is granted by the PTE.

	 
	 

	 
	•    A detailed budget follows and is hereby incorporated into this amendment as Appendix A.

	 
	 

	 
	 
	 
	 
	

                                For clarity: all amounts stated in this amendment are in United States Dollars.
	 

	 
	 
	 
	 
	 

	All other terms and conditions of this Subaward Agreement remain in full force and effect.
	 

	By an Authorized Official of PTE:
	 
	By an Authorized Official of Subrecipient:
	 

	 
	/s/ Lauren Pite
	 
	 
	April 6, 2020
	 
	 
	/s/ Jason Leverone
	 
	 
	April 7, 2020
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	Name:
	Lauren Pite
	 
	 
	Date
	 
	Name:
	Jason Leverone
	 
	 
	Date
	 
	 

	Title:
	Assoc. Director, Office of Sponsored Projects
	 
	Title:
	CFO
	 

Program Director/Principal Investigator (Last, First, Middle):
	
			
	DETAILED BUDGET FOR INITIAL BUDGET PERIOD
DIRECT COSTS ONLY
	FROM
9/1/18
	THROUGH
6/30/20

List PERSONNEL (Applicant organization only)
Use Cal, Acad, or Summer to Enter Months Devoted to Project
Enter Dollar Amounts Requested (omit cents) for Salary Requested and Fringe Benefits
	
											
	NAME
	ROLE ON PROJECT
	Cal. Mnths
	Acad. Mnths
	Summer Mnths
	INST.BASE SALARY
	SALARY REQUESTED
	FRINGE BENEFITS
	TOTAL

	Montgomery, Rusty
	PD/PI
	1.21
	 
	 
	[*]
	[*]
	[*]
	[*]

	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 

	 
	 
	 
	 
	 
	 
	 
	 
	 

	SUBTOTALS
	[*]
	[*]
	 

	CONSULTANT COSTS

	 

	EQUIPMENT (Itemize)

	 

	SUPPLIES  (Itemize by category)
Laboratory Supplies: Compound Synthesis: [*], PK Study: [*], Tissue Distribution Study: [*], Dose Range: [*]

	 

	TRAVEL

	 

	INPATIENT CARE COSTS
	 

	OUTPATIENT CARE COSTS
	 

	ALTERATIONS AND RENOVATIONS  (Itemize by category)

	 

	OTHER EXPENSES  (Itemize by category)

	 

	CONSORTIUM/CONTRACTUAL COSTS
	DIRECT COSTS
	 

	SUBTOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD (Item 7a, Face Page)
	$

	CONSORTIUM/CONTRACTUAL COSTS
	FACILITIES AND ADMINISTRATIVE COSTS
	 

	TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD
	$

Program Director/Principal Investigator (Last, First, Middle):
	
						
	BUDGET FOR ENTIRE PROPOSED PROJECT PERIOD
DIRECT COSTS ONLY

	BUDGET CATEGORY TOTALS
	INITIAL BUDGET PERIOD
(from Form Page 4)
	2nd ADDITIONAL YEAR OF SUPPORT REQUESTED
	3rd ADDITIONAL YEAR OF SUPPORT REQUESTED
	4th ADDITIONAL YEAR OF SUPPORT REQUESTED
	5th ADDITIONAL YEAR OF SUPPORT REQUESTED

	PERSONNEL: Salary and fringe benefits. Applicant organization only.
	 
	 
	 
	 
	 

	CONSULTANT COSTS
	 
	 
	 
	 
	 

	EQUIPMENT
	 
	 
	 
	 
	 

	SUPPLIES
	 
	 
	 
	 
	 

	TRAVEL
	 
	 
	 
	 
	 

	INPATIENT CARE COSTS
	 
	 
	 
	 
	 

	OUTPATIENT CARE COSTS
	 
	 
	 
	 
	 

	ALTERATIONS AND RENOVATIONS
	 
	 
	 
	 
	 

	OTHER EXPENSES
	 
	 
	 
	 
	 

	DIRECT CONSORTIUM/ CONTRACTUAL 
COSTS
	 
	 
	 
	 
	 

	SUBTOTAL DIRECT COSTS
(Sum = Item 8a, Face Page)
	 
	 
	 
	 
	 

	F&A CONSORTIUM/ CONTRACTUAL COSTS
	 
	 
	 
	 
	 

	TOTAL DIRECT COSTS
	 
	 
	 
	 
	 

	TOTAL DIRECT COSTS FOR ENTIRE PROPOSED PROJECT PERIOD
	[*]

JUSTIFICATION. Follow the budget justification instructions exactly. Use continuation pages as  needed.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]